linjc16/ctgov huggingface dataset:
LIMBO : Breast Reconstruction by Lipomodeling Alone or With Flap: Evaluation in Franche-Comté

Study Overview
=================
Brief Summary
-----------------
The Limbo study is a retrospective descriptive study which aims to establish the current state of breast reconstruction surgery at the Besançon University Hospital and Hôpital Nord Franche-Comté, between October 2017 and December 2021.

Official Title
-----------------
Breast Reconstruction by Lipomodeling Alone or With Flap: Evaluation in Franche-Comté

Conditions
-----------------
Breast Cancer, Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who has undergone breast reconstruction using lipomodelling alone or in association with a flap (greater dorsal, DIEP Deep Inferior Epigastric Perforator flap or TRAM Tranverse Rectus Abdominis Myocutaneous Flap), since October 2017. Patient whose follow-up in plastic surgery is considered completed (final result obtained, patient lost to follow-up or not wishing to continue) at the time of data collection. Exclusion Criteria: Patient under 18 at first consultation Opposition of the patient to the collection of her data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of surgical procedures according to the type of breast reconstruction using lipomodelling alone or in combination with a flap | number of surgical procedures | Between october 2017 and 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| description of patients' age | patient age | at inclusion | 
| description of patients' Body Mass Index | Body Mass Index | at inclusion | 
| description of patients' menopause status | menopause status | at the time of data collection | 
| description of patients' smoking status | smoking status | at inclusion | 
| description of patients' diabetes or other medical condition |  | at inclusion | 
| description of patients' relevant medical history | relevant medical history | at inclusion | 
| description of patients' History of breast surgery | hsitory of breast surgery | at inclusion | 
| description of patients' type of cancer | cancer histology | at inclusion | 
| description of patients' type of surgical treatment | type of breast reconstruction using lipomodelling alone or in combination with a flap | at inclusion | 
| description of patients' Type of treatment associated with surgery | Type of treatment associated with surgery | at inclusion | 
| description of Time elapsed between mastectomy and reconstruction | number of month between the date of mastectomy and date of reconstruction | at inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lipodelling, breast reconstruction
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

Study Overview
=================
Brief Summary
-----------------
Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Detailed Description
-----------------
The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Official Title
-----------------
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections - A Retrospective Cohort Study

Conditions
-----------------
Carbapenemase-Producing Enterobacteriaceae

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (≥18) Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022 Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. Exclusion Criteria: Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality at 28 days |  | Mortality at 28 days after infection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carbapenemase, Enterobacteriaceae, VIM-producing strains
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Study Overview
=================
Brief Summary
-----------------
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Official Title
-----------------
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)

Conditions
-----------------
Keratoconus

Intervention / Treatment
-----------------
* Combination Product: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
* Combination Product: Placebo and sham treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of keratoconus Exclusion Criteria: Minimal corneal thickness < 350 microns Non-keratoconic ectatic disease Contraindications or hypersensitivities to any required study medications Pregnancy or breastfeeding Certain concomitant ocular conditions

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active Treatment<br>Epithelium-on corneal cross-linking | Combination Product: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment<br>* Drug: Ribostat riboflavin and sodium iodide ophthalmic solution Device: UV-3000 ultraviolet A light source<br>|
| Placebo Comparator: Control Treatment<br>Placebo and sham for epithelium-on corneal cross-linking | Combination Product: Placebo and sham treatment<br>* Drug: placebo ophthalmic solution Device: UV-3000 light source<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Spectacle-Corrected Distance Visual Acuity (BSCDVA) | BSCDVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The score ranges from 0 to 100, with a higher score representing better visual functioning. | Baseline to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vision-related Quality of Life as Assessed by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25) | The score on the NEI-VFQ-25 ranges from 0 to 100, with a higher score indicating greater functioning. | Baseline to 12 months |
Medical Weight Loss on Pelvic Floor Dysfunction

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the effect of medical weight loss on the symptom of pelvic floor dysfunction in obese and overweight women. The main question it aims to answer is: whether medical weight loss improves symptoms of pelvic floor dysfunctions in obese or overweight women.

Official Title
-----------------
Effect of Medical Weight Loss on Pelvic Floor Dysfunction: a Prospective Observational Study

Conditions
-----------------
Weight Loss, Pelvic Floor Disorders

Intervention / Treatment
-----------------
* Other: Diet and exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or higher BMI 24 kg/m2 or higher Willing to follow the weight loss plan set by the physician follow-up and complete this study Exclusion Criteria: Urinary tract infection or gynecologic reproductive system infection in the past month Treatment history of pelvic floor disorders Pregnancy or delivery in the past half year Women with severe systemic disease No follow-up conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Diet and exercise|Routine intervention included diet control and exercise|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pelvic floor symptoms before and after medical weight loss |  | At least half a year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore the related factors of symptom improvement in pelvic floor dysfunction |  | At least half a year | 
| To explore the improvement of quality of life before and after medical weight loss |  | At least half a year |
Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With IBD

Study Overview
=================
Brief Summary
-----------------
To examine the prevelance of autoimmune disorders and rheumatic manifestations in egyptian patients with inflammatory bowel diseases,and asses the relation between prevelance of autoimmune disorders ,rheumatic manifestations and disease activity of IBD

Official Title
-----------------
Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With Inflammatory Bowel Disease

Conditions
-----------------
IBD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1-adult patients with adiagnosis of IBD according to the validated criteria. 2-patients>18 years without aprevious diagnosis of SPA or other rheumatological manifestations. Exclusion Criteria: 1- patients with active cancer or lymphoproliferative disease. 2-patients with uncontrolled diabetes. 3-patients with unstable ischeamic heart disease or congestive heart failure. 4-patients with acute renal failure. 5-patients already diagnosed with inflammatory or crystal induced arthropathies (including gout and calcium pyrophosphate dehydrate deposition disease) or other autoimmune diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency and risk factors for autoimmune disorders and rheumatic manifestations in Egyptian patients with inflammatory bowel diseases. | to examine the prevelance of autoimmune disorders and rheumatological manifestations in Egyptian patients with inflammatory bowel diseases | 1year |
Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD)

Study Overview
=================
Brief Summary
-----------------
This concerns a study with patients who will undergo endovascular treatment. Blood flow will be measured by 2D Duplex Ultrasound. Contrast data will be collected that will be processed offline.

Official Title
-----------------
Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD)

Conditions
-----------------
Lower Extremity Arterial Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred to the vascular surgery outpatient clinic (LUMC) with PAD Age ≥18 years Superficial femoral artery (SFA) stenosis (>70% occluded) Elective for a percutaneous transluminal angioplasty procedure Written informed consent Exclusion Criteria: Contraindications to angiography, such as severe renal insufficiency (eGFR< 20) Non-correctable bleeding disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients<br>Duplex ultrasound, angiogram, PTA intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood flow | Repeatability and correlation of angiographic hemodynamic measurements compared with the golden standard 2D duplex ultrasound. | performed during a regular PTA intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood flow measurements
The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment

Study Overview
=================
Brief Summary
-----------------
This prospective study is subject to approval of institutional medical research ethics committee. Patient undergoing second cycle IVF will be enrolled into the intervention group. Intervention involved using a clinical decision support tool, Opt-IVF to guide gonadotrophins dosing and trigger dates for a personalized controlled ovarian stimulation cycle based on the distribution of follicle sizes on day 1 and day 5, and hormone dosages given on day 1 to 4. Patients will undergo transvaginal ultrasound exam on day 1 and day 5 of the cycle to determine the number and size of follicles present. The data is used in the Opt-IVF decision support tool to suggest Gonadotropin dosage for D5 and beyond and to recommend the antagonist start day and trigger day. Clinical investigators will not override the Opt-IVF recommended dosage in any patients.

Detailed Description
-----------------
The total dosage of gonadotrophin, number of good quality oocytes and blastocyst will be analyzed from each arm.

Official Title
-----------------
The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment

Conditions
-----------------
Fertility Issues

Intervention / Treatment
-----------------
* Other: total cumulative gonadotrophin usage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing 2nd cycle of IVF Exclusion Criteria: Polycystic ovarian syndrome patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| standard IVF regime protocol based on clinician decision<br>The dosage of gonadotrophin and time of transvaginal ultrasound decided by clinician | Other: total cumulative gonadotrophin usage<br>* total dosage in IU<br>* Other names: number of qood quality blastocyst;|
| clinical decision support tool, Opt-IVF for IVF regime protocol<br>The dosage of gonadotrophin and time of transvaginal ultrasound decided by a clinical decision support tool ( OPt -IVF) | Other: total cumulative gonadotrophin usage<br>* total dosage in IU<br>* Other names: number of qood quality blastocyst;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total cumulative dosage of Gonadotropins | number of total dosage that utilize during one cycle of IVF treatment | for 1 year duration | 
| Total number of matured oocytes | number of matured oocytes following the stimulation protocol | for 1 year duration | 
| total number of good quality blastocyst | total blastocyst achieved after each sti,ulation protocol | for 1 year duration |
Assessment of the Role of Incisura Biopsy in the Staging of Chronic Gastritis

Study Overview
=================
Brief Summary
-----------------
This prospective multicenter study investigates the added benefit of incisura biopsy to correct identification of patients with high-risk chronic gastritis (OLGA stages III-IV). It compares a biopsy protocol with and without a single incisura biopsy in a non-inferiority design.

Official Title
-----------------
Assessment of the Role of INCisura Biopsy in incrEASing the Stage of Chronic Gastritis

Conditions
-----------------
Chronic; Gastritis, Atrophic

Intervention / Treatment
-----------------
* Other: Incisura biopsy analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication to perform upper GI endoscopy for diagnosis or surveillance Exclusion Criteria: lack of informed consent, previously diagnosed advanced gastric cancer, incomplete endoscopy, surgically altered stomach

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Incisura biopsy +<br>this arm has the incisura biopsy scored and added in the OLGA final stage | Other: Incisura biopsy analysis<br>* a pathologist blinded to the other biopsies analyzes the biopsy from the incisura<br>|
| Incisura biopsy -<br>this arm only has corpus and antrum biopsies scored for OLGA staging | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of OLGA III-IV |  | at time of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of OLGIM III-IV |  | at time of enrollment |
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Study Overview
=================
Brief Summary
-----------------
This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

Detailed Description
-----------------
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.

Official Title
-----------------
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Calcitriol
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 patients, hospitalized patients, and patients aged 18-60 years Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control<br>Placebo 2x1 per day | Other: Placebo<br>* Placebo give 2x1 per day for five day<br>|
| Experimental: Calcitriol<br>the treatment group received calcitriol 2x400 iu per day for 5 day | Drug: Calcitriol<br>* The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma<br>* Other names: Oscal;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HsCRP | High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation | Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcitriol, HsCRP
The Predictive Value of Progesterone

Study Overview
=================
Brief Summary
-----------------
To evaluate a 5 ng/ml serum progesterone (P4) threshold policy for the addition of subcutaneous (SC) P4 in artificially prepared frozen embryo transfer cycles treated with vaginal P4. We assess whether the addition of SC P4 rescues cycles with serum P4 <5 ng/ml and we study the impact of not supplementing cycles with serum P4 >5 ng/ml by comparing them with serum P4 cycles above the conventionally proposed cut-off of 10 ng/ml.

Official Title
-----------------
The Predictive Value of the Progesterone Level on the Day of Embryo Transfer in Cryo Cycles

Conditions
-----------------
Progesterone Treshold in Artificial Embryo Transfer Cycles

Participation Criteria
=================
Eligibility Criteria
-----------------
Embryo transfer between March 1st 2021 and March 31st 2023 Determination of progesterone on the day of embryo transfer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 47 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy rate | Fetal heart beat at ultrasound | 11 to 13 weeks after ovulation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | Positive hCG and ultrasound visualisation of the gestational sac | 6 to 8 weeks after ovulation |